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Aim: To report the first Irish outbreak of cfr-mediated linezolid-resistant Staphylococcus
epidermidis.
Methods: Linezolid-resistant S. epidermidis isolated at University Hospital Limerick from
four blood cultures, one wound and four screening swabs (from nine patients) between
April and June 2013 were characterized by pulsed-field gel electrophoresis (PFGE), multi-
locus sequence typing (MLST) and staphylococcal cassette chromosome (SCCmec) typing.
Antibiotic susceptibilities were determined according to the guidelines of the British So-
ciety for Antimicrobial Chemotherapy. The outbreak was controlled through prohibiting
prescription and use of linezolid, adherence to infection prevention and control practices,
enhanced environmental cleaning, isolation of affected patients, and hospital-wide edu-
cation programmes.
Findings: PFGE showed that all nine isolates represented a single clonal strain. MLST
showed that they belonged to ST2, and SCCmec typing showed that they encoded a variant
of SCCmecIII. All nine isolates were cfr positive, and eight isolates were positive for the
G2576T 23S rRNA mutation commonly associated with linezolid resistance. Isolates
exhibited multiple antibiotic resistances (i.e. linezolid, gentamicin, methicillin, clinda-
mycin, ciprofloxacin, fusidic acid and rifampicin). The adopted infection prevention
intervention was effective, and the outbreak was limited to the affected intensive care
unit.Interventions in Infection, Inflammation and Immunity, Graduate Entry Medical School, University of
4703.
Dunne).
Elsevier Ltd on behalf of the Healthcare Infection Society. This is an open access article under the CC
rg/licenses/by-nc-sa/4.0/).
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Antibiotic susceptibility profiles (minimum
Patient Sex PHE MIC Lin Gent
Patient A M >8 128
Patient B M >8 128
Patient C M >8 128
Patient D F >8 128
Patient E M >8 128
Patient F F >8 256
Patient G F >8 256
Patient H F >8 256
Patient I M >8 256
PHE MIC, Public Health England minimum inh
comycin; Clin, clindamycin; Ery, erythromyc
tetracycline; Dap, daptomycin; Fus, fuscidic aConclusions: This is the first documented outbreak of cfr-mediated linezolid-resistant
S. epidermidis in the Republic of Ireland. Despite this, and due to existing outbreak
management protocols, the responsible micro-organism and source were identified effi-
ciently. However, it became apparent that staff knowledge of antimicrobial susceptibil-
ities and appropriate hygiene practices were suboptimal at the time of the outbreak, and
that educational interventions (and re-inforcement) are necessary to avoid occurrence of
antimicrobial resistance and outbreaks such as reported here.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection So-
ciety. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/4.0/).Introduction
Linezolid is a bacteriostatic oxazolidinone antibiotic that
binds to the 50S subunit of bacterial ribosomes and inhibits
protein synthesis.1 It is licensed for use in 70 countries world-
wide, and has been used to treat over four million patients
since its introduction in 2000.2 Linezolid is currently approved
for use in the Republic of Ireland for treatment of multi-drug-
resistant Gram-positive infections, including nosocomial and
community-acquired pneumonia and skin and soft tissue in-
fections, including those caused by meticillin-susceptible and
-resistant staphylococci, coagulase-negative staphylococci and
vancomycin-resistant enterococci.
Recent surveillance data indicate that <1% of Staphylo-
coccus aureus and 2% of coagulase-negative Staphylococcus
spp. (CoNS) are resistant to linezolid.3e5 Mutations in chro-
mosomal genes encoding the central loop of domain V of the
23S rRNA, with the G2576T substitution, are the most
commonly reported resistance mechanism.6 Substitutions for
T2500A, T2504A and G2215A have also been identified in some
staphylococci from clinical infections, as have mutations in the
genes for ribosomal proteins L3, L4 and L22.7,8 In contrast with
mutational resistance, the cfr (chloramphenicol-florfenicol
resistance) gene encodes a transferable 23S rRNA methyl-
transferase conferring resistance to linezolid.9 The cfr gene
encodes resistance to phenicols, lincosamides, oxazolidinones,
pleuromutilins and streptogramin A antimicrobials (the so-
called ‘PhLOPSA phenotype’) and selected macrolides, thus
conferring multi-drug resistance.10 cfr-positive isolates pose an
emerging global health threat,11 and prompt recognition of this
pattern of resistance is needed to prevent the establishment of
reservoirs of cfr-positive bacteria in skin and gut flora.12inhibitory concentrations, m
Ox Pen Tei Van
>16 >8 4 2
>16 >8 4 4
>16 >8 8 2
>16 >8 8 2
>16 >8 8 2
>16 >8 4 2
>16 >8 8 2
>16 >8 8 2
>16 >8 8 2
ibitory concentration; Gent,
in; Lin, linezolid; Cip, ciprofl
cid; Rif, rifampicin; M, maleOutbreaks of cfr-mediated linezolid-resistant S. aureus13,14
and Enterococcus faecalis15 have been described previously.
However, this paper describes the molecular epidemiology,
management and outcomes of the first documented outbreak
of cfr-mediated linezolid-resistant Staphylococcus epidermidis
in the Republic of Ireland.
Methods
Setting
University Hospital Limerick (UHL) is a tertiary referral
university teaching hospital with 483 inpatient beds. Patients
are admitted from the community and from other hospitals
located in the Mid-West of Ireland. The catchment population
of the hospital is 300,000. The intensive care unit (ICU) is a
medical-surgical unit that caters for patients over 16 years of
age. At the time of this outbreak, the ICU had seven beds
(including two isolation rooms). There were three handwashing
stations located within the ICU, with alcohol hand gels at each
bedspace. Two full-time consultant microbiologists and two
infection prevention and control nurses were employed
directly by UHL, and worked on-site at the time of the
outbreak.
Index case identification
The index case patient for this outbreak was identified as a
male in his twenties admitted to UHL in April 2013 following a
deliberate self-poisoning. He was diagnosed with an aspiration
pneumonia, and antimicrobial therapy was commenced with
piperacillin-tazobactam 4.5 g TDS IV and clarithromycin 500mgg/l)
Clin Ery Cip Moxi Quin/Dalf Tet Dap Fus Rif
>8 0.5 >8 0.5 8 >2
>8 0.5 >8 0.5 8 >2
>8 0.5 >8 0.5 0.25 16 >2
>8 0.5 >8 0.5 0.25 16 >2
>8 0.5 >8 0.5 0.5 16 >2
>8 1 >8 0.5 8 >2
>8 1 >8 0.5 8 >2
>8 1 >8 0.5 8 >2
>8 0.5 >8 4 0.5 4 0.5 8 >2
gentamicin; Ox, oxacillin; Pen, penicillin; Tei, teicoplanin; Van, van-
oxacin; Moxi, moxiflocaxin; Quin/Dalf, quinopristin/dalfopristin; Tet,
; F, female.
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taken on presentation. A chest X-ray demonstrated evidence of
a right lower and mid-zone dense consolidation consistent with
an aspiration pneumonia. Antimicrobial therapy was modified
to flucloxacillin 2 g QDS IV, linezolid 600 mg BD IV and cipro-
floxacin 500mg BD IV. Linezolid was added lest the isolate was
proven to be a toxin producer [i.e. Panton Valentine leucocidin
(PVL) positive].
After fivedays, linezolid therapywas stopped as thePVL toxin
result, obtained from a referral laboratory, was negative. During
a subsequent pyrexial episode, blood samples taken from a
femoral line proved positive for CoNS. Paired peripheral blood
cultures were not taken at the same time. Routine antimicrobial
susceptibility testing demonstrated resistance to linezolid, flu-
cloxacillin and gentamicin, but sensitivity to vancomycin and
daptomycin (Table I). This isolate was sent to the Antimicrobial
Resistance and Healthcare Associated Infections Reference Unit
(AMRHAI), Public Health England, London for further analysis.
The index case patient was moved into an isolation room within
the ICU. The AMRHAI results confirmed cfr-positive linezolid-
resistant S. epidermidis, which also harboured the G2576T mu-
tation.16 Followingconfirmationof this result, theprescriptionof
linezolid for all otherpatientswithin thehospitalwas prohibited.
Infection control measure
This first case of linezolid-resistant CoNS at UHL was a major
cause for concern, particularly as colleagues at AMRHAI had
recently issued an alert regarding cfr-mediated resistance that
advised of the associated public health threat. As a consequence,
an outbreak management protocol was initiated that involved
meeting with all key stakeholders, including executive manage-
ment, nursing administration, infection prevention and control,
consultant microbiologists, laboratory managers, bed manage-
ment, hygiene services and the communications team. Contact
tracing of all inpatients who may have been in contact with the
index case patient while in the ICU was conducted by screening
groin and axillae swabs to identify linezolid-resistant CoNS. All
CoNS isolates from samples collected from patients who had
shared the ICU with the index case, or who had occupied the
spaceatany timeup to14days after the indexcasewas confirmed
as positive, were screened for susceptibility to linezolid.
All affected patients in this outbreak were isolated imme-
diately and standard contact precautions were employed. Pa-
tients harbouring linezolid-resistant CoNS were given daily
whole-body washes with 2% chlorhexidine gluconate. All pa-
tients in the ICU who were fit for discharge were cohorted to a
single ward to minimize cross-transmission. Axillae and groin
screens were performed weekly for all patients until discharge.
Enhanced cleaning of the ICU was instigated in parallel with
increased auditing. This involved twice-daily cleaning of
affected areas with detergent, in addition to a ‘deep clean’
with sodium hypochlorite to ‘decontaminate’ the area on
discharge. Hand hygiene audits were also performed with
greater frequency in affected areas, which involved twice-
weekly observational audits at ward level.
Screening of staff for carriage of the organism, air sampling
and environmental sampling were not performed due to
resource limitations. An additional factor influencing the de-
cision not to screen staff was that the ICU is not a closed unit
(i.e. as a matter of clinical policy, patients admitted to the ICU
remain under the care of their primary consultant rather thanthe ICU team), resulting in considerable traffic of medical and
surgical teams to the ICU each day. Instead, a targeted
educational programme focused on hand hygiene, and appro-
priate prescribing was implemented.
Microbiological and molecular detection of linezolid-
resistant S. epidermidis
Linezolid resistance in staphylococci is defined by both the
Clinical Laboratory Standards Institute and the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) as
a minimum inhibitory concentration (MIC) 8mg/l; this
threshold was used to define resistance in this outbreak. In
total, 18 bloodstream isolates were assessed retrospectively
for linezolid susceptibility, and 187 screen specimens (groin
and axillae swabs) were processed in the laboratory.
Screening samples were inoculated on Staph/Strep agar
(Fannin LIP, Galway, Ireland) with a linezolid disc (10 mg) (Oxoid
Ltd, Basingstoke, UK). These were incubated aerobically at
35  1C for 24 h. All suspect linezolid-resistant staphylococcal
isolates were subsequently identified using MALDI-Tof MS
(Bruker Daltonics, Bremen, Germany) as described previ-
ously.17 MICs of linezolid were determined using E-test (bio-
Me´rieux, Marcy l’Etoile, France). All isolates with an MIC of
linezolid 8mg/l, as per EUCAST guidelines in use at the time
in the laboratory,18,19 were referred to AMRHAI for antimicro-
bial susceptibility testing by agar dilution methodology. Iso-
lates were characterized by staphylococcal cassette
chromosome (SCCmec) typing, pulsed-field gel electrophoresis
and multi-locus sequence typing as described previously.20,21
Isolates were screened by polymerase chain reaction (PCR)
for the cfr gene,22 and by PCR and restriction fragment length
polymorphism analysis for the G2576T 23S rRNA mutation
associated with linezolid resistance.
Results
Demographics of affected patients
Between April and June 2013, nine patients (five males, four
females) were found to be harbouring linezolid-resistant
S. epidermidis. The nine affected patients ranged in age
from 28 to 83 years. All patients were admitted to UHL via the
Emergency Department, and were not transfers from other
hospitals. One patient (the index case) was admitted under a
medical service. The other eight patients had complex surgical
admissions including small and large bowel obstructions, uro-
sepsis secondary to calculus, abdominal aortic aneurysm repair
and colorectal malignancy. Eight patients who were deemed to
have been contacts of the index case tested positive. Four of
these patients were identified on screening, and the other four
patients were identified from clinical samples (four blood
cultures, one wound swab) and axillae and groin swabs. CoNS
was not isolated from any deep tissue or intra-operative sam-
ples. Patient data are shown in Table II.
Molecular characteristics of linezolid-resistant
isolates
All nine isolates were positive for the cfr gene, and eight
isolates also bore the G2576T 23S rRNA mutation. The linezolid-
Table II
Patient data
Patient Sex Age (years) Ward Culture site Date of culture Linezolid doses PHE MIC linezolid Outcome
Patient A M 62 Surgical Peripheral BC 28/04/2013 112 8 Discharged
Patient B M 28 ICU Femoral line BC 26/04/2013 18 8 Discharged
Patient C M 56 ICU Femoral line BC 10/05/2013 14 8 Discharged
Patient D F 65 ICU Arterial line BC 05/05/2013 12 8 Discharged
Patient E M 74 ICU Wound swab 19/05/2013 6 8 Died
Patient F F 76 Surgical Axilla/groin swab 28/05/2013 0 8 Discharged
Patient G F 72 Surgical Axilla/groin swab 29/05/2013 28 8 Discharged
Patient H F 83 Surgical Axilla/groin swab 29/05/2013 25 8 Discharged
Patient I M 35 Surgical Axilla/groin swab 03/06/2013 0 8 Discharged
ICU, intensive care unit; BC, blood culture; PHE, Public Health England; MIC, minimum inhibitory concentration; M, male; F, female.
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cultures: one inpatient on the general surgical ward (from
peripheral blood cultures) and three ICU patients (two from
femoral line blood cultures, one from arterial line blood cul-
ture). Pulsed-field gel electrophoresis showed that all nine
isolates represented a single strain. Multi-locus sequence
typing showed that they belonged to ST2, and SCCmec typing
showed that they encoded a variant of SCCmecIII.
Only seven of the nine patients had received treatment with
linezolid previously. All isolates were resistant to linezolid,
gentamicin, methicillin, clindamycin, ciprofloxacin, fusidic
acid and rifampicin; teicoplanin resistance was variable. All
isolates were sensitive to daptomycin, vancomycin and qui-
nopristin/dalfopristin. The full antimicrobial sensitivity testing
results are outlined in Table I.
Discussion
This cfr-mediated linezolid-resistant S. epidermidis
outbreak was the first such outbreak in the Republic of Ireland.
Although dissemination to the other ICU patients was rapid and
vigorous, multi-disciplinary interventions limited, and led to
rapid termination of, the outbreak. While the blood culture of
the index case was fortuitously identified as being linezolid
resistant, it is not unusual for these samples, in the study
institution and others, to be less than fully characterized with
regard to species identification and/or antimicrobial suscep-
tibility testing unless the patient is in critical care or has
prosthetic material in situ. This poses an important question as
to whether, generally, there may be under-ascertainment of
linezolid-resistant CoNS and whether CoNS may be acting as a
reservoir of cfr-mediated resistance in hospitals.
Previous research has demonstrated that the cfr gene is
capable of horizontal transfer between staphylococci.10 In
Europe, cfr was initially identified on a plasmid from a bovine
isolate of Staphylococcus sciuri in 2000;23 its occurrence among
animal isolates appears to have been influenced by the use of
florfenicol in the veterinary industry. Worldwide, the incidence
of linezolid-resistant CoNS is currently 28 times that of
linezolid-resistant S. aureus.16
Clinical reports of linezolid resistance date from 2007 when
Toh et al.24 reported the first cfr-mediated linezolid-resistant
clinical isolate of meticillin-resistant S. aureus (MRSA). Since
then, notable reports have included two US-based cases of cfr-
mediated resistance in clinical isolates of S. epidermidis and
S. aureus in 2008,25 a 2013 case report of cfr-mediatedlinezolid-resistant MRSA blood culture isolate from an ICU in
Barcelona, Spain,26 and characterization of cfr-mediated MRSA
and S. haemolyticus with fatal outcomes originating from a
German group.27
A report detailing a 2008 outbreak of cfr-mediated linezolid-
resistant S. aureus28 in Madrid, Spain was particularly similar to
the UHL outbreak, affecting 12 high-risk critically ill ICU pa-
tients; two patients infected with linezolid-resistant S. aureus
and three patients colonized with linezolid-resistant S. aureus
died. The Spanish ICU was not closed to admissions during their
17-week outbreak. Measures to control the outbreak included
isolation with contact precautions and restriction of linezolid
prescription, as were employed at UHL. It would have been
interesting to compare linezolid consumption prior to the
outbreak between the two studies, but this was not mentioned
in the Spanish paper. However, at UHL, use of linezolid has
been increasing steadily over the past two years. Antimicrobial
inpatient consumption at UHL is collated on a quarterly basis,
with data reported as defined daily doses/100 bed-days used.
Between 2011 and 2012, there was a 3% increase in the pre-
scription of intravenous linezolid and a 28% increase in the
prescription of oral linezolid. Between 2012 and 2013 (when
this outbreak occurred), the use of intravenous linezolid
increased by a further 11%. Despite the increase in the use of
intravenous linezolid between 2011 and 2013, the median level
of use at UHL during this period was consistently lower than
that of other Irish hospitals categorized as having a similar
patient mix.
In the UHL outbreak, the authors were unable to perform
environmental or staff screening. In the Madrid outbreak, no
staff members were found to be colonized with linezolid-
resistant S. aureus, but 15 of 91 (17%) swabbed environ-
mental surfaces were contaminated by linezolid-resistant
S. aureus, and may have contributed to the prolonged nature
of the outbreak. At UHL, staff knowledge of the mechanisms by
which antimicrobial resistance emerges was lacking, and
awareness of the transmissibility of Gram-positive organisms
via contaminated hands of healthcare workers and equipment
(e.g. stethoscopes, blood pressure cuffs and intravenous drip
stands, etc.) was poor. Subsequently, human and financial re-
sources were mobilized to implement a hospital-wide educa-
tion programme for all healthcare staff, in liaison with the
antimicrobial pharmacist, which targeted management,
nursing, medical, household and administration staff. Twelve
months after this outbreak, regular education sessions
continue to be provided to all staff, and a specific lecture on
C. O’Connor et al. / Journal of Hospital Infection 90 (2015) 316e321320the local antimicrobial resistance patterns is provided to all
medical and surgical trainee doctors during induction. No
further instances of cfr-mediated linezolid resistance were
identified between July 2013 and June 2014.
Conclusions
This is the first report of cfr-mediated linezolid resistance in
S. epidermidis in the Republic of Ireland. Linezolid is a rela-
tively novel agent and, therefore, an outbreak was unex-
pected. However, in retrospect, this was inevitable given the
increasing consumption of linezolid at UHL. The hospital has
learned from this outbreak and practice has changed accord-
ingly. Linezolid susceptibility is monitored in CoNS for all ICU
patients using a linezolid disc-based process. The judicious use
of linezolid with consultant-only prescribing, application of
strict infection control measures, isolation of all patients from
this outbreak when they subsequently presented for outpatient
appointments or admission, enhanced daily environmental
cleaning, a low threshold for characterizing CoNS identified in
samples such as blood cultures and wound swabs from critical
care areas and other high-risk hospital patients, and the pres-
ence of a visible antimicrobial stewardship team on the hos-
pital wards have been, and will continue to be, essential for the
preservation of linezolid as a valuable therapeutic agent.
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